within Pharmacolibrary.Drugs.ATC.S;

model S01ED05_1
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 0.006416666666666667,
    adminDuration  = 600,
    adminMass      = 1 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0045,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>S01ED05_1</td></tr><td>route:</td><td>ophthalmic</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Carteolol is a non-selective beta-adrenergic blocker primarily used as an ophthalmic solution to reduce intraocular pressure in the treatment of glaucoma and ocular hypertension. It is generally approved and used today in several countries in the form of eye drops.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for carteolol following topical ocular administration. No published human ocular PK model exists; estimates are based on systemic absorption from ocular route.</p><h4>References</h4><ol><li><p>Tokuda, N, et al., &amp; Fujisawa, S (2012). Effects of a long-acting ophthalmic formulation of carteolol containing alginic acid on the corneal epithelial barrier function and water retentive effect. <i>Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics</i> 28(2) 123–128. DOI:<a href=&quot;https://doi.org/10.1089/jop.2011.0101&quot;>10.1089/jop.2011.0101</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/22217390/&quot;>https://pubmed.ncbi.nlm.nih.gov/22217390</a></p></li><li><p>Séchoy, O, et al., &amp; Trinquand, C (2000). A new long acting ophthalmic formulation of carteolol containing alginic acid. <i>International journal of pharmaceutics</i> 207(1-2) 109–116. DOI:<a href=&quot;https://doi.org/10.1016/s0378-5173(00)00539-1&quot;>10.1016/s0378-5173(00)00539-1</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11036236/&quot;>https://pubmed.ncbi.nlm.nih.gov/11036236</a></p></li><li><p>Zimmerman, TJ (1993). Topical ophthalmic beta blockers: a comparative review. <i>Journal of ocular pharmacology</i> 9(4) 373–384. DOI:<a href=&quot;https://doi.org/10.1089/jop.1993.9.373&quot;>10.1089/jop.1993.9.373</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/7906296/&quot;>https://pubmed.ncbi.nlm.nih.gov/7906296</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end S01ED05_1;
